Allogene Therapeutics, Inc. (ALLO) is a publicly traded company in the Unknown sector. Across all available filings, 24 corporate insiders have executed 279 transactions totaling $179.4M, demonstrating a bearish sentiment with -$113.8M in net insider flow. The most recent transaction on Dec 18, 2025 involved a transaction of 47,700 shares valued at $0.
No significant insider buying has been recorded for ALLO in the recent period.
No significant insider selling has been recorded for ALLO in the recent period.
Based on recent SEC filings, insider sentiment for ALLO is bearish with an Insider Alignment Score of 18/100 and a net flow of -$113.8M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Allogene Therapeutics, Inc. (ALLO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 24 insiders are actively trading ALLO stock, having executed 279 transactions in the past 90 days. The most active insider is James G. Coulter (Executive), who has made 8 transactions totaling $82.5M.
Get notified when executives and directors at ALLO file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 18, 2025 | A. Kazam Joshua | Executive | Option Exercise | 47,700 | $N/A | $0 | |
| Nov 17, 2025 | Machinas Beneski Benjamin | Executive | Sale | 786 | $1.22 | $959 | |
| Oct 21, 2025 | M. Parker Geoffrey | Executive | Sale | 36,744 | $1.26 | $46.3K | |
| Aug 21, 2024 | Martin Douglas Earl | Executive | Payment | 28,310 | $2.79 | $79.0K | |
| Jun 18, 2024 | M. Messemer Deborah | Executive | Sale | 18,641 | $2.28 | $42.5K | 10b5-1 |
| Jun 5, 2024 | M. Messemer Deborah | Executive | Award | 122,950 | $N/A | $0 | |
| Jun 5, 2024 | B. Humer Franz | Executive | Award | 61,475 | $N/A | $0 | |
| Jun 5, 2024 | L. Sato Vicki | Executive | Award | 61,475 | $N/A | $0 | |
| May 30, 2024 | B. Humer Franz | Executive | Sale | 11,200 | $2.34 | $26.2K | |
| May 16, 2024 | D. Chang David | Executive | Award | 344,828 | $2.90 | $1.0M | Large |
| May 16, 2024 | M. Parker Geoffrey | Executive | Award | 344,828 | $2.90 | $1.0M | Large |
| May 16, 2024 | Belldegrun Arie | Executive | Award | 344,828 | $2.90 | $1.0M | Large |
| May 16, 2024 | Belldegrun Arie | Executive | Purchase | 1,724,137 | $2.90 | $5.0M | Large |
| Apr 22, 2024 | L. Moore Timothy | Executive | Payment | 17,360 | $3.47 | $60.2K | |
| Mar 14, 2024 | D. Chang David | Executive | Payment | 53,393 | $4.33 | $231.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 108 | $146.6M | 73.9% |
Purchase(P) | 13 | $32.8M | 16.5% |
Exercise(M) | 31 | $8.8M | 4.4% |
Other(J) | 39 | $6.0M | 3.0% |
Award(A) | 61 | $3.0M | 1.5% |
Payment(F) | 10 | $1.1M | 0.6% |
Gift(G) | 8 | $0 | 0.0% |
Conversion(C) | 9 | $0 | 0.0% |
Insider selling pressure at Allogene Therapeutics, Inc. has increased, with 24 insiders executing 279 transactions across all time. Total sales of $146.6M significantly outpace purchases of $32.8M, resulting in a net outflow of $113.8M. This selling activity appears largely discretionary, which may warrant closer attention from investors.